About: Dodecaborate is a research topic. Over the lifetime, 347 publications have been published within this topic receiving 5472 citations. The topic is also known as: dodecaborate(12).
TL;DR: In this paper, the closo-dodecaborate anion and its derivatives are reviewed with a focus on potential applications in medical applications, with emphasis on medical applications.
Abstract: Synthesis and chemical properties of the closo-dodecaborate anion [B 1 2 H 1 2 ] 2 - and its derivatives are reviewed. Attention is also paid to potential applications of the closo-dodecaborate derivatives with emphasis on medical applications. A review with 325 references.
TL;DR: Salting-in effects revealed dodecaborates as superchaotropic dianions as well as micromolar affinities reached, which are the highest known for this native CD.
Abstract: Dodecaborate anions of the type B12X122− and B12X11Y2− (X=H, Cl, Br, I and Y=OH, SH, NH3+, NR3+) form strong (Ka up to 106 L mol−1, for B12Br122−) inclusion complexes with γ-cyclodextrin (γ-CD). The micromolar affinities reached are the highest known for this native CD. The complexation exhibits highly negative enthalpies (up to −25 kcal mol−1) and entropies (TΔS up to −18.4 kcal mol−1, both for B12I122−), which position these guests at the bottom end of the well-known enthalpy-entropy correlation for CDs. The high driving force can be traced back to a chaotropic effect, according to which chaotropic anions have an intrinsic affinity to hydrophobic cavities in aqueous solution. In line with this argument, salting-in effects revealed dodecaborates as superchaotropic dianions.
TL;DR: The good cyclability and high water/thermal stability render it suitable for real industrial applications, and the practical separation performance of C3 H8 /CH4 and C2 H6 / CH4 was confirmed by dynamic breakthrough experiments.
Abstract: A novel 3D metal-organic framework BSF-1 based on the closo-dodecaborate cluster [B12 H12 ]2- was readily prepared at room temperature by supramolecular assembly of CuB12 H12 and 1,2-bis(4-pyridyl)acetylene. The permanent microporous structure was studied by X-ray crystallography, powder X-ray diffraction, IR spectroscopy, thermogravimetric analysis, and gas sorption. The experimental and theoretical study of the gas sorption behavior of BSF-1 for N2 , C2 H2 , C2 H4 , CO2 , C3 H8 , C2 H6 , and CH4 indicated excellent separation selectivities for C3 H8 /CH4 , C2 H6 /CH4 , and C2 H2 /CH4 as well as moderately high separation selectivities for C2 H2 /C2 H4 , C2 H2 /CO2 , and CO2 /CH4 . Moreover, the practical separation performance of C3 H8 /CH4 and C2 H6 /CH4 was confirmed by dynamic breakthrough experiments. The good cyclability and high water/thermal stability render it suitable for real industrial applications.
TL;DR: The possible clinical implications of the new and improved boron-based biologically active compounds for BNCT that are reported to have in vivo and/or in vitro efficacy are focused on.
Abstract: Boron compounds now have many applications in a number of fields, including Medicinal Chemistry. Although the uses of boron compounds in pharmacological science have been recognized several decades ago, surprisingly few are found in pharmaceutical drugs. The boron-containing compounds epitomize a new class for medicinal chemists to use in their drug designs. Carboranes are a class of organometallic compounds containing carbon (C), boron (B), and hydrogen (H) and are the most widely studied boron compounds in medicinal chemistry. Additionally, other boron-based compounds are of great interest, such as dodecaborate anions, metallacarboranes and metallaboranes. The boron neutron capture therapy (BNCT) has been utilized for cancer treatment from last decade, where chemotherapy and radiation have their own shortcomings. However, the improvement in the already existing (BPA and/or BSH) localized delivery agents or new tumor-targeted compounds are required before realizing the full clinical potential of BNCT. The work outlined in this short review addresses the advancements in boron containing compounds. Here, we have focused on the possible clinical implications of the new and improved boron-based biologically active compounds for BNCT that are reported to have in vivo and/or in vitro efficacy.